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Abstract: Primary ciliary dyskinesia (PCD) is a rare genetic disease that causes recurrent respiratory
infections. People with PCD may be at higher risk of severe coronavirus disease 2019 (COVID-19),
and therefore vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is
important. We studied vaccination willingness, speed of vaccination uptake, side effects, and changes
in social contact behaviour after vaccination in people with PCD. We used data from COVID-PCD,
an international participatory cohort study. A COVID-19 vaccination questionnaire was emailed to
participants in May 2021 and 423 participants from 31 countries replied (median age: 30 years, range
1–85 years; 261 (62%) female). Vaccination uptake and willingness were high, with 273 of 287 adults
(96%) being vaccinated or willing to be in June 2021; only 4% were hesitant. The most common
reason for hesitancy was fear of side effects, reported by 88%. Mild side effects were common, but no
participant reported severe side effects. Half of the participants changed their social behaviour after
vaccination by seeing friends and family more often. The high vaccination willingness in the study
population might reflect the extraordinary effort taken by PCD support groups to inform people
about COVID-19 vaccination. Clear and specific information and involvement of representatives is
important for high vaccine uptake.
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1. Introduction
Vaccination against coronavirus disease 2019 (COVID-19) has proven effective in prevent-
ing transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1,2] with
most countries now vaccinating against COVID-19 [3]. Several vaccines against COVID-19
have been approved [4–6], the first of which were administered at the end of 2020. Priority
was given to people considered at high risk of severe COVID-19, such as the elderly and
people with chronic diseases [7]. By August 2021, many European countries had vaccinated
most of the people willing to get vaccinated. Vaccination willingness has generally been
high in Europe, but an important proportion of the general population in several countries
still hesitates to get vaccinated [8–10]. In some countries, vaccine uptake has only reached
50% of the general population [11].
There are few data about vaccination hesitancy among people who are at high risk of
severe COVID-19, particularly in populations with rare diseases such as primary ciliary
dyskinesia (PCD). PCD is a rare genetic multi-system disease where dysfunctional cilia
lead to impaired mucociliary clearance, situs defects, congenital heart defects, and other
health problems [12–16]. PCD is characterized by chronic upper and lower airway dis-
ease [13,17–20], reduced lung function, and in some cases supplementary oxygen [21–25].
At the beginning of the pandemic, people with PCD and other chronic respiratory diseases
were thought to be at high risk of severe COVID-19 disease. To study the incidence and
severity of COVID-19 in people with PCD, we set up a participatory study, the COVID-
PCD, in collaboration with PCD support groups from all over the world [26]. First results
from the study showed a low infection rate and mostly mild COVID-19 disease [27]. People
with PCD were strongly recommended to get vaccinated against SARS-CoV-2; however,
to date there is no information about vaccination willingness, vaccination uptake, and side
effects among people with PCD. Studies including people with other pre-existing health
conditions show varying vaccination willingness [28–30]. The speed of vaccination rollout
differs between countries, and it is unclear how quickly high-risk populations are being
vaccinated. The aim of this study was to describe COVID-19 vaccination willingness
and hesitancy among people with PCD, to study the speed of vaccination uptake, assess
the vaccines’ reported side effects, and investigate changes in social contact behaviour
after vaccination.
2. Materials and Methods
2.1. Study Design and Inclusion Criteria
We used data from COVID-PCD, an international prospective cohort study designed
to follow people with PCD during the COVID-19 pandemic period (clinicaltrials.gov:
NCT04602481). COVID-PCD is a participatory research project where people with PCD
play an active role at all stages of research, including study design and content, piloting,
and communication of results. Details about study methods and initial results have been
published previously [26,27]. In summary, COVID-PCD includes people of any age from
any country with suspected or confirmed PCD. Data are collected through anonymous
online questionnaires that are adapted to three age groups; children below 14 years, ado-
lescents between 14 and 17 years, and adults aged 18 years or older. Parents complete the
questionnaires for children below 14 years, although the children are encouraged to partici-
pate. Adolescents and adults complete questionnaires themselves. The study is available
in five languages, including English, German, Spanish, Italian, and French. Recruitment
started on 31 May 2020. The Cantonal Ethics Committee of Bern approved the study (Study
ID: 2020-00830). Participants provide consent to participate online at the time of registration
to the study. This article follows the STROBE reporting recommendations [31].
2.2. Study Procedures
PCD support groups helped recruit study participants by contacting people living
with PCD through social media and email networks and encouraged them to take part
in the study. Participants register in the COVID-PCD study through a link on the study
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website (Available online: www.covid19pcd.ispm.ch, accessed on 29 May 2021). At regis-
tration, participants read detailed information about the study and provide consent online.
Participants first complete a baseline questionnaire with questions about their disease,
symptoms, and SARS-CoV-2 infections experienced prior to joining the study [32]. There-
after they receive a short follow-up questionnaire each week with questions on incident
SARS-CoV-2 infections, COVID-19 vaccinations, current symptoms, and social contact
behaviour. Intermittently, participants receive short special questionnaires that focus on
specific topics. This paper presents data from a special questionnaire on vaccinations
that was sent to participants on 29 May 2021 as well as data on vaccinations retrieved
through the weekly questionnaire. Participants received up to two reminders if they did
not respond to the special questionnaire. Participating PCD support groups were strongly
involved in the development of all questionnaires. All data were entered in a Research
Electronic Data Capture (REDCap) database (Available online: www.project-redcap.org/
(accessed on 15 December 2021)) [33,34], which is hosted by the Swiss medical registries
and data linkage centre (SwissRDL) at the University of Bern, Switzerland.
2.3. Information about COVID-19 Vaccinations
The special questionnaire on COVID-19 vaccinations asked whether participants had
already been vaccinated, and if yes, which vaccine they received (Supplementary Table S1).
We also asked whether participants changed their social contact behaviour after vaccination.
Unvaccinated participants were asked about vaccination willingness. We distinguished
between people who planned to get vaccinated, were not sure whether to get vaccinated,
or did not want to get vaccinated. Additional questions focused on reasons for and
against vaccination.
The routine weekly questionnaire asked whether participants had been vaccinated
since completion of the previous weekly questionnaire, which date they were vaccinated,
whether it was the first or the second vaccination, and which side effects they experienced.
We asked about side effects separately after the first and the second vaccine.
2.4. Statistical Analyses
We described the demographics of the study participants, vaccination uptake, vac-
cination willingness and hesitancy, reasons for and against getting vaccinated, side ef-
fects, changes in social behaviour using number and proportion for categorical variables,
and mean and standard deviation (SD) or median and interquartile range for continuous
variables. We described vaccination willingness and hesitancy per age group. We chose the
cut-off of 12 years between the child and adolescent age groups because several vaccines
had been approved for children down to the age of 12 years by June 2021. We described
speed of vaccination uptake using the date of the first vaccination extracted from the
weekly follow-up questionnaires and used this to compare how quickly participants living
in different countries were vaccinated. To study factors associated with reported side
effects we used multilevel logistic regression. We ran a regression with each side effect as a
dependent variable (no side effects, local pain or swelling around injection site, tiredness,
fever, muscle or bone pain, other) and added the following explanatory variables: age,
sex, vaccine type, and vaccine timing (first or second injection, included as a separate
level representing repeated measurements within an individual). The logistic regression
analyses are reported as odds ratios (ORs) and 95% confidence intervals (95% CIs). Our
dataset had less than 2% missing values of single variables and records with missing data
were excluded from the analysis. We used STATA version 15 for statistical analysis.
3. Results
In total, 423 of the 689 study participants (61%) completed the special questionnaire
on vaccinations. The median age was 30 years (age range: 1–85 years, interquartile
range 12 to 47) and 261 (62%) were female (Supplementary Table S2). Study participants
were from 31 different countries with the highest numbers from the UK (n = 88; 21%),
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Germany (n = 76; 18%), USA (n = 64; 15%), and Switzerland (n = 31; 7%). Participants
who completed the special questionnaire on vaccinations were slightly older, more often
female, and more often from European countries than those who did not complete it
(Supplementary Table S2).
Vaccination uptake and willingness were high in the study population. Among the
287 adults, 263 (92%) had already been vaccinated, 3 (1%) had an appointment, 7 (2%)
planned to get vaccinated, 7 (2%) were hesitant to get vaccinated, and 7 (2%) did not
plan to get vaccinated (Table 1). People who were unsure or unwilling to get vaccinated
more often came from Germany, Switzerland, and other European countries, but we found
no difference in age or sex (Supplementary Table S3). Among the 41 adolescent study
participants, 17 (41%) had already been vaccinated, and among children below 12 years,
2 of 95 (2%) were vaccinated. Five adolescents (12%) and 8 children (8%) did not plan
to get vaccinated, even if the vaccine were to be approved for persons their age. Among
participants who had been vaccinated, most had received Pfizer-BioNTech (48%) followed
by AstraZeneca (22%), Moderna (15%), and other (15%).
Table 1. Self-reported vaccination willingness, vaccination uptake, and vaccine type among people with primary ciliary
dyskinesia by age (n = 423) (COVID-PCD study, May 2021).
Participants Who Completed the Vaccination
Questionnaire (n = 423)
Adults Aged ≥ 18 y Adolescents * Aged 12–17 y Children * ≤ 11 y
n = 287 n = 41 n = 95
n (%) n (%) n (%)
Vaccination willingness
Already vaccinated or willing to be vaccinated 273 (96) 30 (73) 66 (69)
Hesitant (not sure whether to get vaccinated) 7 (2) 6 (15) 21 (22)
Resistant (do not plan to get vaccinated) 7 (2) 5 (12) 8 (8)
Vaccinated against COVID-19
Yes, I received 2 doses 198 (69) 7 (17) 1 (1)
Yes, I received 1 dose 65 (23) 10 (24) 1 (1)
No, but I have an appointment to get vaccinated 3 (1) 0 1 (1)
No 21 (7) 24 (59) 92 (97)
Participants who received 1 or 2 vaccine doses (n = 282) n = 263 n = 17 n = 2
Type of vaccine
Pfizer-BioNTech 120 (46) 13 (76) 1 (50)
Moderna 41 (16) 1 (6) 0
AstraZeneca 63 (24) 0 0
Janssen/Johnson and Johnson 3 (1) 0 0
I don’t know 36 (14) 3 (18) 1 (50)
* Data for children below 14 years of age were reported by their parents. Abbreviations: y, years.
The most important reasons for getting vaccinated were to “protect themselves and
others from infection” (99%) and to “stop the pandemic” (95%) (Figure 1). Less important
reasons to get vaccinated were that the vaccination would enable them to travel and
would make activities such as going to the fitness centre possible. Reasons against getting
vaccinated were similar among those who did not want to get vaccinated (n = 20) and those
who were not sure whether to get vaccinated (n = 31) (Figure 2). In total, 88% of those who
were hesitant to get vaccinated reported that they were concerned about side effects and
75% reported concern that the vaccine development had been too rushed. Few participants
reported reasons relating to disbelief in the effectiveness of vaccines (8%) or not knowing
how to get the vaccine (4%).
The vaccination uptake and the speed of vaccination rollout differed between countries
(Supplementary Figures S1 and S2). Participants living in the UK were vaccinated faster
than in all other countries. By mid-February 2021, 80% of the adults who had completed
the special vaccination questionnaire had received at least one vaccine and by the end of
June 2021, 100% had received at least one vaccine. The second fastest country to vaccinate
was the USA, followed by Switzerland. The country in which the vaccination rollout
was slowest was Australia, where by June 2021, 80% of participants had received at least
one vaccine.
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Reported side effects after vaccination were common but mild; nobody reported se-
vere side effects. The most common side effect was redness, swelling, or pain around the
injection site, which was reported by 60% of participants, followed by tiredness, headache,
aching muscles, and fever (Figure 3). Other side effects such as nausea, vomiting, diar-
rhoea, and stomachache were rare. Participants reported side effects more often after the
second vaccine than the first. Younger participants more often reported fever, headache,
and muscle pain than older participants (Table 2). Participants who received Moderna or As-
traZeneca reported side effects more often than participants who received Pfizer-BioNTech.
Vaccines 2021, 9, x FOR PEER REVIEW 5 of 13 
 
 
effects and 75% reported concern that the vaccine development had been too rushed. Few 
participants reported reasons relating to disbelief in the effectiveness of vaccines (8%) or 
not knowing how to get the vaccine (4%). 
 
Figure 1. Reasons for getting vaccinated among participants who already got vaccinated or wanted to get vaccinated among 
adults (n = 272) and children and adolescents (n = 94). Responses rated from very important to unimportant. (COVID-PCD 
study, May 2021). Abbreviations: A = adults aged 18 years or above; C = children and adolescents below 18 years. 





































































Very important Somewhat important Neither
Somewhat unimportant Unimportant
Figure 1. Reasons for getting vaccinated among participants who already got vaccinated or wanted
to get vaccinated among adults (n = 272) and children and adolescents (n = 94). Responses rated
from very important to unimportant. (COVID-PCD study, May 2021). Abbreviations: A = adults
aged 18 years or above; C = children and adolescents below 18 years.




Figure 2. Agreement (rated as somewhat or strongly) with reasons against getting vaccinated among those who did not 
want to get vaccinated against COVID-19 (n = 20) and those who were not sure whether to get vaccinated (n = 34). (COVID-
PCD study, May 2021). 
The vaccination uptake and the speed of vaccination rollout differed between coun-
tries (Supplementary Figures S1 and S2). Participants living in the UK were vaccinated 
faster than in all other countries. By mid-February 2021, 80% of the adults who had com-
pleted the special vaccination questionnaire had received at least one vaccine and by the 
end of June 2021, 100% had received at least one vaccine. The second fastest country to vac-
cinate was the USA, followed by Switzerland. The country in which the vaccination rollout 
was slowest was Australia, where by June 2021, 80% of participants had received at least 
one vaccine. 
Reported side effects after vaccination were common but mild; nobody reported se-
vere side effects. The most common side effect was redness, swelling, or pain around the 
injection site, which was reported by 60% of participants, followed by tiredness, headache, 
aching muscles, and fever (Figure 3). Other side effects such as nausea, vomiting, diarrhoea, 
and stomachache were rare. Participants reported side effects more often after the second 
0 20 40 60 80 100
I am concerned about side effects
Concerned that vaccine development was too rushed
I first want to see how the vaccine works on other people
I am concerned about the ingredients in the vaccine
I am concerned that the vaccine will affect my fertility
I think I would only get mild symptoms
I don't like people telling me what I have to do
I would rather risk getting COVID-19 than the vaccine
Someone I know had a severe side effect  which…
I think  enough other people will get the vaccine
I don't like needles
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Percent of participants (%)
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Figure 2. Agreement (rated as somewhat or strongly) with reasons against getting vaccinated among those who did
not want to get vaccinated against COVID-19 (n = 20) and those who were not sure whether to get vaccinated (n = 34).
(COVID-PCD study, May 2021).
Half of the partici ants changed their social behaviour after the first vaccine, and three
quarters after the second vaccine (Figure 4). After the first vaccine, participants started to
go grocery shopping more often (reported by 23%) as well as to meet family and friends
(20%). After the second vaccine, there was an increase in the frequency of participants
seeing family and friends (50%), attending appointments such as physiotherapy (34%),
and going shopping (29%).
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Figure 3. Self-reported side effects after first (n = 238) and after second vaccine (n = 214) among
vaccinated participants including 95% confidence intervals (COVID-PCD study, May 2021). Other
side effects included nausea, vomiting, diarrhoea, stomachache, dizziness, chills, breathlessness,
cough, congestion, and swollen lymph nodes.
Table 2. Odds ratios from multilevel logistic regression analyses of reporting side effects after
COVID-19 vaccination adjusted for age, sex, first or second injection, and type of vaccine (n = 266)
(COVID-PCD study, May 2021).
OR Lower 95% CI Upper 95% CI p-Value
No side effects
Age (continuous, per year increase) 0.98 0.95 1.00 0.126
Sex (female vs. male) 1.80 0.72 4.50 0.208
Injection (second vs. first) 1.57 0.79 3.11 0.198
Vaccine (ref: Pfizer-BioNTech)
Moderna 2.34 0.61 8.97 0.215
AstraZeneca 0.89 0.33 2.42 0.818
Local pain/swelling
Age (continuous, per year increase) 0.99 0.96 1.01 0.320
Sex (female vs. male) 1.58 0.72 3.49 0.249
Injection (second vs. first) 1.45 0.86 2.45 0.168
Vaccine (ref: Pfizer-BioNTech)
Moderna 3.32 1.11 9.92 0.032
AstraZeneca 0.54 0.22 1.30 0.167
Tiredness
Age (continuous, per year increase) 0.99 0.97 1.01 0.374
Sex (female vs. male) 1.54 0.81 2.93 0.190
Injection (second vs. first) 2.19 1.33 3.61 0.002
Vaccine (ref: Pfizer-BioNTech)
Moderna 2.95 1.23 7.09 0.016
AstraZeneca 1.12 0.55 2.29 0.751
Fever
Age (continuous, per year increase) 0.97 0.95 0.99 0.015
Sex (female vs. male) 0.90 0.43 1.90 0.791
Injection (second vs. first) 3.12 1.64 5.94 0.001
Vaccine (ref: Pfizer-BioNTech)
Moderna 5.64 2.06 15.42 0.001
AstraZeneca 7.57 2.93 19.53 <0.001
Vaccines 2021, 9, 1496 8 of 13
Table 2. Cont.
OR Lower 95% CI Upper 95% CI p-Value
Headache
Age (continuous, per year increase) 0.98 0.96 1.00 0.052
Sex (female vs. male) 1.73 0.83 3.62 0.147
Injection (second vs. first) 2.31 1.33 4.00 0.003
Vaccine (ref: Pfizer-BioNTech)
Moderna 3.15 1.21 8.20 0.019
AstraZeneca 6.30 2.65 15.00 <0.001
Muscle/bone pain (not around
injection site)
Age (continuous, year increase) 0.97 0.95 0.99 0.003
Sex (female vs. male) 0.79 0.45 1.38 0.403
Injection (second vs. first) 1.59 0.99 2.56 0.057
Vaccine (ref: Pfizer-BioNTech)
Moderna 2.34 1.11 4.96 0.026
AstraZeneca 4.73 2.34 9.53 <0.001
Other
Age (continuous, per year increase) 1.01 0.97 1.04 0.751
Sex (female vs. male) 1.34 0.45 4.01 0.604
Injection (second vs. first) 0.68 0.78 3.61 0.183
Vaccine (ref: Pfizer-BioNTech)
Moderna 3.93 0.95 16.19 0.058
AstraZeneca 4.22 1.24 14.38 0.021
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Figure 4. Proportion of participants who reported how they changed their social behaviour after first and second vaccina-
tions compared to before getting vaccinated (n = 282) (C I -P study, May 2021).
4. Discussion
This international rticipatory study found that most people with PCD were already
vaccinated against COVID-19 or willing to be by the end of May 2021. Only 2% of adults
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did not plan to get vaccinated, for which the most common reasons were concerns about
side effects and concerns that the vaccines had been developed too quickly. Side effects
were common but mild, and were reported more often after the second vaccine than the
first, more often by younger participants than older, and more often among participants
vaccinated with Moderna or AstraZeneca than with Pfizer-BioNTech. Half of the partici-
pants changed their social behaviour after the first vaccine, with the main difference being
an increase in time spent with family and friends.
4.1. Interpretation and Comparison with Other Studies
Vaccination willingness in our study population was high, with 96% of adults and
73% of adolescents aged 12–17 years being vaccinated or willing to be by June 2021. Two
children below the age of 12 years had been vaccinated and 69% of parents reported that
they were willing to get their child vaccinated if the vaccine were to be approved for
children. Few studies are published on COVID-19 vaccination uptake and willingness
with comparison across different countries. Most of these data stem from convenience
sampling, which has a high risk of selection bias [35]. One study from the UK included
more than two million unselected adults and found a vaccination willingness of 94% [36],
similar to what we observed in our study population. However, other studies show
lower vaccination willingness in the general population. A study from the UK showed a
vaccination willingness of 75%, with willingness being higher among study participants
born in the UK compared to other countries of birth [37]. In a study from the USA including
more than 75,000 adults, 80% of the study participants had been vaccinated or were willing
to be by the end of March 2021 [38]. In our study, we found that unwillingness to get
vaccinated was more commonly reported in countries such as Switzerland and Germany
than in countries such as the UK (Supplementary Table S3). When looking at whole-country
vaccination rates from Our World in Data [11], overall vaccination rates were also higher
in the UK than for example Switzerland. Few studies have reported data on vaccination
willingness and uptake in people with chronic respiratory disease. A study in 273 adults
with severe asthma showed high willingness to get vaccinated, with only 6% refusing
vaccination, which is in line with our findings [30]. In contrast with our findings, only 20%
reported side effects after the first and second doses of vaccine. A study from India among
adults with diabetes found a vaccination willingness of 64% [28]. Reasons for not getting
vaccinated included fear of side effects, not knowing about the vaccine, and needing to
discuss with family members. In our study, nobody reported not knowing about the
vaccine. PCD support groups around the world have actively informed members about
COVID-19 vaccines and encouraged people with PCD to get vaccinated. This information
and encouragement may have contributed to the vaccination uptake and willingness in
our population.
We found that reported side effects were common but mild, which has also been
observed in the general population. In a large prospective cohort study in more than half a
million adults from the UK, local side effects such as pain, swelling, and redness around
the injection site were reported by 72% after the first dose of Pfizer-BioNTech and by 59%
after the first dose of AstraZeneca [39]. Systemic side effects such as headache, fatigue,
chills, and fever were reported by 14% after a dose of Pfizer-BioNTech and by 34% after
AstraZeneca. Similar findings were seen in two studies among healthcare workers [40,41].
In our population, all side effects were more often reported after the second injection
than after the first. We found that systemic side effects were more often reported by
participants who received Moderna or AstraZeneca than by people who received Pfizer-
BioNTech, which is in line with what was found in the UK study [39]. Younger persons
were more likely to report side effects than older persons, which has also been shown
in other studies and may be explained by a stronger immune response to the vaccine in
younger people [42]. Other studies reported that women were more likely to experience
side effects [39,41], although we did not observe this. In summary, our study does not
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suggest that people with PCD have more or worse side effects from the COVID-19 vaccines
than the general population.
We found that half of the study participants changed their social behaviour after
receiving the first dose of the vaccine. Participants started to see family and friends more
often, but only very few (1% of participants) reported not using additional protective
measures after vaccination. There are few published data from the general population
on changes in social behaviour after vaccination but in a UK study among 23,287 adults,
the authors found no evidence that people stopped social distancing after vaccination [43].
In our study, we did not ask whether participants kept social distancing when going out
or seeing friends and family, but around 20% said that they did shake hands with people
more often after getting vaccinated. This is in contrast to previous studies that found that
people with PCD are very careful in protecting themselves against COVID-19 by avoiding
public places and always wearing facemasks [44].
4.2. Strengths and Limitations
A major strength of this study is the large sample size of people with PCD from all over
the world. PCD is a rare disease, and it can be difficult to recruit participants for research
studies. COVID-PCD is a participatory study that was initiated, designed, and tested in
collaboration with people who have PCD. This improved study participation. The PCD
support groups advertised the special questionnaire on COVID-19 vaccinations via social
media and email networks before it was sent out, which may have improved the response
rate. The questionnaire was made available in five languages, which ensured that fewer
people were excluded by language barriers. A limitation is that the study population may
not be representative for all people with PCD but rather mainly of those who are in contact
with a patient support group. It is difficult to ascertain the representativeness of the study
population, as we have no information about people with PCD who did not participate in
the COVID-PCD study. When we compare those who completed the special questionnaire
on vaccinations (61%) to those who did not (41%), we see that non-responders were slightly
younger than those who responded and tended to come from non-European countries
(Supplementary Table S2). It is possible that respondents were more vaccine-willing than
non-responders, which would have led to an overestimation of vaccine uptake. Another
limitation is that the sample size, although large for a rare disease, had limited power to
detect rare side effects of vaccination.
5. Conclusions
In summary, this study found that vaccination willingness and uptake was high
among people with PCD, which may reflect the extraordinary effort made by PCD support
groups to inform people with PCD about the advantages of vaccination. No severe side
effects were reported. Clear and specific public information about COVID-19 vaccine safety
is important for a high vaccine uptake, and thus for better protection against COVID-19.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/vaccines9121496/s1. Table S1: Formulation of questions and answers from the special ques-
tionnaire on COVID-19 vaccinations sent to participants in May 2021. (COVID-PCD study, May 2021);
Table S2: Characteristics of people with primary ciliary dyskinesia who completed the special ques-
tionnaire on COVID-19 vaccinations and those who did not. (COVID-PCD study, May 2021); Table S3:
Demographic characteristics of adults with primary ciliary dyskinesia who were already vaccinated
or willing to be compared to adults who were unwilling to get vaccinated. (COVID-PCD study,
May 2021); Figure S1: Speed of vaccination uptake among adults in the COVID-PCD in countries
with the highest number of participants. (COVID-PCD study, May 2021). Abbreviations: UK, United
Kingdom; USA, United states of America; GER, Germany; IT, Italy; CH, Switzerland; FR, France;
and AU, Australia. Figure S2: Cumulative percent of COVID-PCD study participants vaccinated
(black thick line), compared with nationwide data from selected countries (coloured lines, data source:
GitHub [45], accessesd on 24 August 2021).
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